Validation of a single-platform, volumetric, flow cytometry for CD4 T cell count monitoring in therapeutic mobile unit

Journal of Translational Medicine

Laurent Bélec¹  Luc Montagnier³  Vittorio Colizzi³  Fru F Angwafo III⁴  Jeanne Ngogang²  Bertrand Sagnia³  François-Xavier Mbopi-Kéou⁴ 

[1] Laboratoire de Virologie, Hôpital Européen Georges Pompidou, and Faculté de Médecine Paris Descartes, Université Paris Descartes (Paris V), Sorbonne Paris Cité, Paris, France;Centre Hospitalier-Universitaire de Yaoundé, and Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, Yaoundé, Cameroun;Centre International de Référence Chantal Biya, Yaoundé, Cameroun;Laboratoire National de Santé Hygiène Mobile, Ministère de la Santé Publique, and Faculté de Médecine et des Sciences Biomédicales, Université de Yaoundé I, Yaoundé, Cameroun

关键词: Therapeutic mobile unit;    Resource-limited settings;    HIV;    CD4 T cell count;    Flow cytometry;   

Others  :  1207773
DOI  :  10.1186/1479-5876-10-22

 received in 2011-08-24, accepted in 2012-02-06,  发布年份 2012

【 摘 要 】

Background

A mobile health unit may be useful to follow up adult and pediatric patients on antiretroviral treatment and living in remote areas devoid of laboratory facilities. The study evaluated the use of the simplified, robust, single-plateform, volumetric, pan-leucogating Auto40 flow cytometer (Apogee Flow Systems Ltd, Hemel Hempstead, UK) for CD4 T cell numeration in a mobile unit, compared against a reference flow cytometry method.

Methods

The therapeutic mobile unit of the Laboratoire National de Santé Hygiène Mobile, Yaoundé, Cameroon, was equipped with the Auto40. A FACSCalibur flow cytometer (Becton Dickinson Immuno-cytometry System, San Jose, CA, USA) was used as reference method. EDTA-blood samples from volunteers were first subjected to CD4 T cell count in the mobile unit, and an aliquot was sent within 4 hours to Centre International de Référence Chantal Biya, Yaoundé, for FACSCalibur assay.

Results

Two HIV screening campaigns with the mobile unit were organised in December 2009 and January 2010. The campaign in the suburb of Yaoundé which was 20 km from the reference laboratory included 188 volunteers comprising 93 children less than 5 years old. The campaign in Ambang Bikok (53 km far from Yaoundé) included 69 adult volunteers. In Yaoundé suburb, mean ± standard deviation (SD) CD4 T cell count was 996 ± 874 cells/μl by Auto40, and 989 ± 883 cells/μl by FACSCalibur; in Ambang Bikok, mean ± SD CD4 T cell count was 1041 ± 317 cells/μl by Auto40, and 1032 ± 294 cells/μl by FACSCalibur. Results by Auto40 and FACSCalibur were highly correlated in Yaoundé (r² = 0.982) as in Ambang Bikok (r² = 0.921). Bland-Altman analysis showed a close agreement between Auto40 and FACSCalibur results expressed in absolute count as in percentage in Yaoundé and Ambang Bikok. When pooling the 257 CD4 T cell count measurements, the Auto40 yielded a mean difference of +7.6 CD4 T cells/μl higher than by reference flow cytometry; and the sensitivity and specificity of Auto40 in enumerating absolute CD4 T cell counts of less than 200 cells/μl were 87% and 99%, respectively, and in enumerating absolute CD4 T cell counts of less than 350 cells/μl were 87% and 98%, respectively. The intrarun and interun precisions of the Auto40 assay assessed in the mobile unit were 5.5% and 7.9%, respectively.

Conclusions

The Auto40 flow cytometer installed in a therapeutic mobile unit and operated far from its reference laboratory gave a perfect correlation with the reference method, and could be useful in carrying out immunological monitoring of HIV-infected patients living in areas without access to laboratory facilities.

【 授权许可】

   
2012 Mbopi-Kéou et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]World Health Organization: World Health Organization (WHO) recommendations Antiretroviral therapy for HIV infection in adults and adolescents. Antiretroviral therapy for a public health approach 2010 revision. [http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf] webcite
• [2]World Health Organization: World Health Organization (WHO) recommendations. Antiretroviral therapy for HIV infection in infants and children: toward universal access. [http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf] webcite
• [3]Bélec L, Bonn JP: Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less. Future Microbiol 2011, 6:1251-1260.
• [4]WHO laboratory recommendations by level [http://www.who.int/hiv/amds/WHOLabRecommendationBylevelFinal.pdf] webcite
• [5]WHO consultation on technical and operational recommendations for scale-up of laboratory services and monitoring HIV antiretroviral therapy in resource-limited settings [http://www.who.int/hiv/pub/meetingreports/scaleup/en/] webcite
• [6]Diagnostics and laboratory technology (DLT) website [http://www.who.int/diagnostics_laboratory/en/] webcite
• [7]Mandy F, Nicholson J, McDougal J, CDC: Guidelines for performing single-platform absolute CD4R T-cell determinations with CD45 gating for persons infected with human immunodeficiency virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003, 52(RR-2):1-13.
• [8]Dieye TN, Vereecken C, Diallo AA, Ondoa P, Diaw PA, Camara M, Karam F, Mboup S, Kestens L: Absolute CD4 T-cell counting in resource-poor settings: direct volumetric measurements versus bead-based clinical flow cytometry instruments. J Acquir Immune Defic Syndr 2005, 39:32-37.
• [9]O'Gorman MR, Zijenah LS: CD4 T cell measurements in the management of antiretroviral therapy--a review with an emphasis on pediatric HIV-infected patients. Cytometry B Clin Cytom 2008, 74:S19-S26.
• [10]Dieye TN, Diaw PA, Daneau G, Wade D, Niang MS, Camara M, Diallo AA, Kane CT, Ndiaye HD, Mbengue B, Dieye A, Kestens L, Mboup S: Evaluation of a flow cytometry method for CD4 T cell enumeration based on volumetric primary CD4 gating using thrermoresistant reagents. J Immunol Methods 2011, 372:7-13.
• [11]Barbesti S, Soldini L, Carcelain G, Guignet A, Colizzi V, Mantelli B, Corvaglia A, Tran-Minh T, Dorigatti F, Autran B, Lazzarin A, Beretta A: A simplified flow cytometry method of CD4 and CD8 cell counting based on thermoresistant reagents: implications for large scale monitoring of HIV-infected patients in resource-limited settings. Cytometry B Clin Cytom 2005, 68:43-51.
• [12]UNAIDS: Report on the global AIDS epidemic 2010. [http://www.unaids.org/globalreport/Global_report.htm] webcite
• [13]Taiwo BO, Murphy RL: Clinical applications and availability of CD4 T cell count testing in sub-Saharan Africa. Cytometry B Clin Cytom 2008, 74B(Suppl 1):S11-S18.
• [14]Larsen CH: The fragile environments of inexpensive CD4 T-cell enumeration in the least developed countries: strategies for accessible support. Cytometry B Clin Cytom 2008, 74B(Suppl 1):S107-S116.
• [15]Mbopi-Kéou FX, Ongolo-Zogo P, Angwafo F, Ndumbe PM, Bélec L: High impact of mobile units for mass HIV testing in Africa. AIDS 2007, 21:1994-1996.
• [16]O'Connor CA, Patsdaughter CA, Grindel CG, Taveira PF, Steinberg JL: A mobile HIV education and testing program: bringing services to hard-to-reach populations. AIDS Patient Care STDS 1998, 12:931-937.
• [17]Vidal L: Disclosure and counselling: elements for a review of the literature about African experiences [in French]. Psychopathol Africaine 1994, XXVI:155-188.
• [18]Kranzer K, Wood R, Bekker LG: Earlier HIV diagnosis--are mobile services the answer? S Afr Med J 2010, 100:671-674.
• [19]Grabbe KL, Menzies N, Taegtmeyer M, Emukule G, Angala P, Mwega I, Musango G, Marum E: Increasing access to HIV counseling and testing through mobile services in Kenya: strategies, utilization, and cost-effectiveness. J Acquir Immune Defic Syndr 2010, 54:317-323.
• [20]Hoffman RA, Hansen WP: Simple and rapid measurement of human T lymphocytes and their subclasses in peripheral blood. Proc Natl Acad Sci USA 1980, 77:4914-4917.
• [21]Brando B, Barnett D, Janossy G, Mandy F, Autran B, Rothe G, Scarpati B, D'Avanzo G, D'Hautcourt JL, Lenkei R, Schmitz G, Kunkl A, Chianese R, Papa S, Gratama JW: Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. Cytometry 2000, 42:327-346.
• [22]Mercolino TJ, Connelly MC, Meyer EJ, Knight MD, Parker JW, Stelzer GT, DeChirico G: Immunologic differentiation of absolute lymphocyte count with an integrated flow cytometric system: a new concept for absolute T cell subset determination. Cytometry 1995, 22:48-59.
• [23]Passing H, Bablok W: A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983, 21:709-720.
• [24]Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1:307-310.
• [25]Bland JM, Altman DG: Measuring agreement in method comparison studies. Stat Methods Med Res 1999, 8:135-160.
• [26]World Health Organization: Antiretroviral therapy for HIV treatment of adults and adolescents: recommendations for a public health approach 2006 revision. [http://www.who.int/hiv/pub/guidelines/adult/en/index.html] webcite
• [27]Cohen J: A coefficient of agreement for nominal scales. Educ Psychol Meas 1960, 20:37-46.
• [28]Fredlund VG, Nash J: How far should they walk? Increasing antiretroviral therapy access in a rural community in northern KwaZulu-Natal, South Africa. J Infect Dis 2007, 196(Suppl 3):S469-S473.
• [29]Loubiere S, Boyer S, Protopopescu C, Bonono CR, Abega SC, Spire B, Moatti JP: Decentralization of HIV care in Cameroon: increased access to antiretroviral treatment and associated persistent barriers. Health Policy 2009, 92:165-173.
• [30]Wools-Kaloustian KK, Sidle JE, Selke HM, Vedanthan R, Kemboi EK, Boit LJ, Jebet VT, Carroll AE, Tierney WM, Kimaiyo S: A model for extending antiretroviral care beyond the rural health centre. J Int AIDS Soc 2009, 12:22. BioMed Central Full Text
• [31]Rosen S, Fox MP, Gill CJ: Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoSMed 2007, 4:e298.
• [32]Bedelu M, Ford N, Hilderbrand K, Reuter H: Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis 2007, 196(Suppl 3):S464-S468.
• [33]Boyer S, Eboko F, Camara M, Abé C, Nguini ME, Koulla-Shiro S, Moatti JP: Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon. AIDS 2010, 24:S5-S15.
• [34]Chan AK, Mateyu G, Jahn A, Schouten E, Arora P, Mlotha W, Kambanji M, van Lettow M: Outcome assessment of decentralization of antiretroviral therapy provision in a rural district of Malawi using an integrated primary care model. Trop Med Int Health 2010, 15(Suppl 1):90-97.
• [35]Fatti G, Grimwood A, Bock P: Better antiretroviral therapy outcomes at primary healthcare facilities: an evaluation of three tiers of ART services in four South African provinces. PLoS One 2010, 5:e12888.
• [36]Geng EH, Nash D, Kambugu A, Zhang Y, Braitstein P, Christopoulos KA, Muyindike W, Bwana MB, Yiannoutsos CT, Petersen ML, Martin JN: Retention in care among HIV infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep 2010, 7:234-244.
• [37]UNAIDS outlook report 2010 [http://data.unaids.org/pub/outlook/2010/20100713_outlook_report_web_en.pdf] webcite
• [38]Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, Kglatwane J, Kinsman J, Kwasa R, Maridadi J, Moroka TM, Moyo S, Nakiyemba A, Nsimba S, Ogenyi R, Oyabba T, Temu F, Laing R: Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care 2007, 19:658-665.
• [39]Miller CM, Ketlhapile M, Rybasack-Smith H, Rosen S: Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Health 2010, 15(Suppl 1):48-54.
• [40]Murtagh MM: UNITAIDS Technical Report. HIV/AIDS diagnostic landscape. [http:/ / www.unitaid.eu/ images/ marketdynamics/ publications/ unitaid_md_technical_report_diagnos tics_landscape_web.pdf] webcite 2011.
• [41]Jani IV, Sitoe NE, Chongo PL, Alfai ER, Quevedo JI, Tobaiwa O, Lehe JD, Peter TF: Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing. AIDS 2011, 25:807-812.
• [42]Dube C, Nozaki I, Hayakawa T, Kakimoto K, Yamada N, Simpungwe JB: Expansion of antiretroviral treatment to rural health centre level by a mobile service in Mumbwa district, Zambia. Bull World Health Organ 2010, 88:788-791.
• [43]Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA: Cost-effectiveness of HIV treatment in resource-poor settings: the case of Cote d'Ivoire. N Engl J Med 2006, 355:1141-1153.
• [44]Loubiere S, Meiners C, Sloan C, Freedberg KA, Yazdanpanah Y: Economic evaluation of ART in resource-limited countries. Curr Opin HIV AIDS 2010, 5:225-231.
• [45]Walensky P, Ciaranello CL, Park J-E, Freedberg KA: Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: A review of the current literature. Clin Infect Dis 2010, 51:85-82.
• [46]DiFranceisco W, Holtgrave DR, Hoxie N, Reiser WJ, Resenhoeft R, Pinkerton SD, Vergeront J: HIV seropositivity rates in outreach-based counseling and testing services: program evaluation. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:282-288.
• [47]Ellen JM, Bonu S, Arruda JS, Ward MA, Vogel R: Comparison of clients of a mobile health van and a traditional STD clinic. J Acquir Immune Defic Syndr 2003, 32:388-393.
• [48]Babigumira JB, Sethi AK, Smyth KA, Singer ME: Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda. Pharmacoeconomics 2009, 27:963-973.